Remicade Biosimilars Market - Size, Share, Outlook,
and Opportunity Analysis, 2018-2026
Biosimilar refers to biotherapeutic product that is similar in terms of quality, efficacy, and
safety to an existing licensed reference therapeutic drug. Biological products are the fastest
growing class of therapeutic products, as they offer additional treatment options and help in
lowering healthcare costs. Biosimilars are almost identical copies of the originally approved
drugs and can be manufactured only when the patent for the original innovator drug expires.
These products are highly sensitive to smallest changes in manufacturing procedure, as these
drugs possess high molecular complexity. Remicade (Infliximab) refers to a chimeric monoclonal
antibody biologic licensed by U.S. FDA in 1998, as an innovative product indicated for the
treatment of Crohn’s disease in adults and children. The monoclonal antibody drug was first
developed in partnership by Janssen Biotech, Inc. and Merck & Co. The Remicade was later
approved for its use in the treatment of ulcerative colitis, plague psoriasis, rheumatic arthritis,
and spinal psoriatic arthritis in combination with methotrexate. Later, various pharmaceutical
manufacturers developed biosimilars to infliximab, which lowered market share of Remicade
due to cost-effective prices.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1769
Market Dynamics
Increasing incidence of autoimmune diseases such as plaque psoriasis and rheumatoid
arthritis are expected to drive growth of the Remicade biosimilar market size. According
to the American Autoimmune Related Disease Association, around 50 million American
suffered from autoimmune diseases in the U.S. in 2017. Moreover, faster reaction rates
of these biosimilars due to their availability in the form of intravenous mode of
administration is further expected to increase the adoption of Remicade biosimilar over
the forecast period. Furthermore, patent expiry of the branded versions is expected to
increase the number of biosimilars for its branded counterparts thereby increasing the
demand for Remicade biosimilar. However, stringent regulatory guidelines for